根治性前列腺切除术后PSA最低值出现时机与生化复发风险
基于SEARCH数据库1939例根治性前列腺切除术后1-6个月内可测超敏PSA最低值的男性回顾性分析。PSA最低值可测且出现时间较短者生化复发风险增加;约半数术后前3个月PSA可测者在3-6个月随访中PSA水平下降。
要点
- PSA最低值不可测者中,最低值出现时间与生化复发无关(1.0-2.9 vs 3-6个月:HR 0.86,P=0.46)。
- PSA最低值可测者,无论出现时间如何,生化复发风险均增加(3-6个月:HR 1.81,P=0.024;1.0-2.99个月:HR 3.75,P<0.001)。
- 术后1-3个月PSA可测者中,53%在术后3-6个月随访时PSA更低,其中32%转为不可测、21%降低但仍可测。
核心结论
- 根治性前列腺切除术后,PSA最低值可测且出现时间较短者生化复发风险增加。
- 约半数术后前3个月PSA可测者在术后3-6个月随访中PSA水平下降,若未来研究证实,这对基于术后前3个月PSA值考虑辅助治疗的患者有重要意义。
研究设计与样本
- SEARCH数据库1939例1998至2015年间接受根治性前列腺切除术、术后1-6个月有超敏PSA最低值的男性的回顾性分析。
- 采用Cox模型对PSA最低值和最低值出现时间与最低值至生化复发时间进行单变量和多变量分析,校正人口学特征、肿瘤特征和术前PSA。
主要发现
- PSA最低值不可测者中,最低值出现时间与生化复发无关(1.0-2.9 vs 3-6个月:HR 0.86,P=0.46)。
- 无论最低值出现时间如何,PSA最低值可测者生化复发风险增加:最低值出现时间3-6个月者HR 1.81,P=0.024;1.0-2.99个月者HR 3.75,P<0.001(参照为最低值不可测且出现时间3-6个月)。
- 术后1-3个月PSA可测者中,53%在术后3-6个月随访时PSA水平更低,其中32%转为不可测,21%降低但仍可测。
关键数值与推荐
- PSA最低值不可测者中,最低值出现时间1.0-2.9个月 vs 3-6个月:HR 0.86,P=0.46。
- PSA最低值可测且出现时间3-6个月:HR 1.81,P=0.024(参照为最低值不可测且出现时间3-6个月)。
- PSA最低值可测且出现时间1.0-2.99个月:HR 3.75,P<0.001(参照为最低值不可测且出现时间3-6个月)。
- 术后1-3个月PSA可测者中,53%在术后3-6个月随访时PSA更低,其中32%转为不可测、21%降低但仍可测。
临床怎么用
- 原文结论指出,若未来研究证实,术后前3个月PSA可测者中约半数在3-6个月随访时PSA下降这一现象,对基于术后前3个月PSA值考虑辅助治疗的患者有重要意义。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the association between the prostate-specific antigen (PSA) nadir level and the time to nadir (TTN) with biochemical recurrence (BCR) risk after radical prostatectomy (RP) in the Shared Equal-Access Research Cancer Hospital (SEARCH) database. MATERIALS AND METHODS: This is a retrospective analysis of 1939 men from the SEARCH database treated with RP between 1998 and 2015 with available ultrasensitive PSA nadir within 1-6 months after RP. Uni- and multivariable analyses of PSA nadir and TTN with time from nadir to BCR were performed with Cox models (adjusted for demographics, tumor features, and preoperative PSA). RESULTS: Among men with an undetectable PSA nadir, the TTN was unrelated to BCR (1.0-2.9 vs 3-6 months: hazard ratio [HR] 0.86, P = .46). Regardless of TTN, men with detectable nadir had an increased risk of BCR (TTN of 3-6 months: HR 1.81, P = .024; TTN of 1.0-2.99 months: HR 3.75, P <.001 vs undetectable nadir and TTN of 3-6 months). Among men with a detectable PSA at 1-3 months, 53% had a lower PSA level during follow-up 3-6 months after RP, which was undetectable in 32% and lower but still detectable in 21%. CONCLUSION: In the post-RP setting, men with both a detectable nadir and a shorter TTN had an increased risk of BCR. Intriguingly, about half of the men with a detectable PSA in the first 3 months after RP had a lower PSA level during follow-up between 3 and 6 months after RP. If confirmed in future studies, this has important implications for patients considering adjuvant therapy based on postoperative PSA values in the first 3 months after RP.
引用
- Skove SL, Howard LE, Aronson WJ, et al. Timing of Prostate-specific Antigen Nadir After Radical Prostatectomy and Risk of Biochemical Recurrence. Urology. 2017. PMID: 28735016. doi:10.1016/j.urology.2017.07.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。